DE69626416D1 - Salze von chinolinderivaten als nk3 antagonisten - Google Patents

Salze von chinolinderivaten als nk3 antagonisten

Info

Publication number
DE69626416D1
DE69626416D1 DE69626416T DE69626416T DE69626416D1 DE 69626416 D1 DE69626416 D1 DE 69626416D1 DE 69626416 T DE69626416 T DE 69626416T DE 69626416 T DE69626416 T DE 69626416T DE 69626416 D1 DE69626416 D1 DE 69626416D1
Authority
DE
Germany
Prior art keywords
antagonists
salts
chinoline derivatives
chinoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69626416T
Other languages
English (en)
Other versions
DE69626416T2 (de
Inventor
Arnaldo Giardina
Carlo Farina
Mario Grugni
Francesco Raveglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
GlaxoSmithKline SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline SpA filed Critical GlaxoSmithKline SpA
Application granted granted Critical
Publication of DE69626416D1 publication Critical patent/DE69626416D1/de
Publication of DE69626416T2 publication Critical patent/DE69626416T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69626416T 1995-11-24 1996-11-22 Salze von chinolinderivaten als nk3 antagonisten Expired - Lifetime DE69626416T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9524137.8A GB9524137D0 (en) 1995-11-24 1995-11-24 Novel compounds
PCT/EP1996/005210 WO1997019928A1 (en) 1995-11-24 1996-11-22 Salts of quinoline derivatives as nk3 antagonists

Publications (2)

Publication Number Publication Date
DE69626416D1 true DE69626416D1 (de) 2003-04-03
DE69626416T2 DE69626416T2 (de) 2003-12-24

Family

ID=10784449

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69626416T Expired - Lifetime DE69626416T2 (de) 1995-11-24 1996-11-22 Salze von chinolinderivaten als nk3 antagonisten

Country Status (23)

Country Link
US (3) US6355654B1 (de)
EP (1) EP0876348B1 (de)
JP (1) JP4377454B2 (de)
KR (1) KR19990071599A (de)
CN (1) CN1207728A (de)
AR (1) AR004970A1 (de)
AT (1) ATE233243T1 (de)
AU (1) AU722451B2 (de)
BR (1) BR9611729A (de)
CA (1) CA2238312A1 (de)
CZ (1) CZ158198A3 (de)
DE (1) DE69626416T2 (de)
ES (1) ES2192621T3 (de)
GB (1) GB9524137D0 (de)
HU (1) HUP9903584A3 (de)
IL (1) IL124352A0 (de)
MX (1) MX9804106A (de)
NO (1) NO310866B1 (de)
NZ (1) NZ323389A (de)
PL (1) PL326927A1 (de)
TR (1) TR199800925T2 (de)
WO (1) WO1997019928A1 (de)
ZA (1) ZA969812B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) * 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
AU4038000A (en) 1999-03-29 2000-10-16 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
AU4802500A (en) * 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
EP1891012A2 (de) * 2005-06-03 2008-02-27 AstraZeneca AB Chinolinderivate als nk3-antagonisten
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
JP2009504572A (ja) * 2005-08-02 2009-02-05 スミスクライン・ビーチャム・コーポレイション キノリン誘導体の合成方法
EP1915363A1 (de) * 2005-08-11 2008-04-30 AstraZeneca AB Oxopyridylchinolinamide als modulatoren des nk3-rezeptors
AR057130A1 (es) * 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
JP2009508944A (ja) * 2005-09-21 2009-03-05 アストラゼネカ・アクチエボラーグ Ｎｋ−３受容体リガンドとしてのｎ−オキソ複素環及びｎ−オキソ−アルキルキノリン−４−カルボキシアミド類
TW200804288A (en) 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
CN101410392A (zh) * 2006-01-27 2009-04-15 阿斯利康(瑞典)有限公司 酰胺取代的喹啉类化合物
FR2979173B1 (fr) * 2011-08-19 2013-08-16 St Microelectronics Grenoble 2 Commutateur analogique basse tension
MX344308B (es) * 2011-11-03 2016-12-13 Merck Sharp & Dohme Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE246677T1 (de) * 1994-05-27 2003-08-15 Smithkline Beecham Farma Chinolinderivate als tachykinin nk3 rezeptor antagonisten
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
CA2238312A1 (en) 1997-06-05
CN1207728A (zh) 1999-02-10
HUP9903584A3 (en) 2001-10-29
US20020077335A1 (en) 2002-06-20
NO310866B1 (no) 2001-09-10
US20020156097A1 (en) 2002-10-24
PL326927A1 (en) 1998-11-09
AU722451B2 (en) 2000-08-03
BR9611729A (pt) 1999-04-06
US6355654B1 (en) 2002-03-12
WO1997019928A1 (en) 1997-06-05
KR19990071599A (ko) 1999-09-27
ATE233243T1 (de) 2003-03-15
DE69626416T2 (de) 2003-12-24
NO982332L (no) 1998-05-22
TR199800925T2 (xx) 2001-05-21
GB9524137D0 (en) 1996-01-24
ZA969812B (en) 1998-05-22
CZ158198A3 (cs) 1998-10-14
EP0876348A1 (de) 1998-11-11
IL124352A0 (en) 1998-12-06
ES2192621T3 (es) 2003-10-16
AR004970A1 (es) 1999-04-07
US6432977B1 (en) 2002-08-13
NZ323389A (en) 2000-02-28
JP2000500770A (ja) 2000-01-25
AU1031997A (en) 1997-06-19
MX9804106A (es) 1998-09-30
JP4377454B2 (ja) 2009-12-02
EP0876348B1 (de) 2003-02-26
NO982332D0 (no) 1998-05-22
HUP9903584A2 (hu) 2000-02-28

Similar Documents

Publication Publication Date Title
DE69531458D1 (de) Chinolinderivate als tachykinin nk3 rezeptor antagonisten
DE69628334D1 (de) Chinolin derivate als nk3 antagoniste
DE69304243D1 (de) Chinolin-Verbindungen als Angiotensin-II-Antagoniste
DE69431604D1 (de) Benzofuranderivate als tachykininantagonisten
DE69626416D1 (de) Salze von chinolinderivaten als nk3 antagonisten
BR9612465A (pt) Compostos heterocíclicos
FI932517A0 (fi) Antagonister av angiotensin II
DE69631647D1 (de) Erfassung von möglichem betrügerischen gebrauch von kommunikation
LV10099A (lv) Bicikliski heterocikliski atvasinajumi
NO20000226D0 (no) Nye spiroazabicykliske heterocykliske forbindelser
DE69127791D1 (de) Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten
DE69634416D1 (de) Chinolin-derivate
DE69605430D1 (de) Chinolin-2-on derivate als serotonin antagonisten
DE69612852D1 (de) BENZO[g]CHINOLINDERIVATE
NO974605L (no) Nye heterosykliske forbindelser
DE69617995D1 (de) Indolalkylderivate von benzodioxanmenthylamin als 5-ht1a rezeptor liganden
PT696194E (pt) Utilizacao de derivados de indole como antagonistas de 5ht1
ATE325118T1 (de) Piperazinoderivate als neurokinin-antagonisten
DE59508900D1 (de) Verwendung von Dibrom-thiophen-carbonsäure-Derivaten als Mikrobizide
NO992268D0 (no) N-bundne sulfonamider av heterocykliske tioestere
DE69634183D1 (de) Substituierte Heterocyclen
DE69328701D1 (de) Diazabicycloderivate als 5-HT3-Antagonisten
NO981216L (no) Nye heterosykliske forbindelser
ATE208764T1 (de) Isazole derivate als fibrinogen-rezeptor- antagonisten
DE59407285D1 (de) Imidazolochinoxalinonderivate als eaa antagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition